LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: The role of claudin-2 in kidney function and dysfunction.

    Nyimanu, Duuamene / Behm, Christine / Choudhury, Sonali / Yu, Alan S L

    Biochemical Society transactions

    2023  Volume 51, Issue 4, Page(s) 1437–1445

    Abstract: Claudin-2 is a tight junction protein expressed in leaky epithelia where it forms paracellular pores permeable to cations and water. The paracellular pore formed by claudin-2 is important in energy-efficient cation and water transport in the proximal ... ...

    Abstract Claudin-2 is a tight junction protein expressed in leaky epithelia where it forms paracellular pores permeable to cations and water. The paracellular pore formed by claudin-2 is important in energy-efficient cation and water transport in the proximal tubules of the kidneys. Mounting evidence now suggests that claudin-2 may modulate cellular processes often altered in disease, including cellular proliferation. Also, dysregulation of claudin-2 expression has been linked to various diseases, including kidney stone disease and renal cell carcinoma. However, the mechanisms linking altered claudin-2 expression and function to disease are poorly understood and require further investigation. The aim of this review is to discuss the current understanding of the role of claudin-2 in kidney function and dysfunction. We provide a general overview of the claudins and their organization in the tight junction, the expression, and function of claudin-2 in the kidney, and the evolving evidence for its role in kidney disease.
    MeSH term(s) Claudin-2/metabolism ; Kidney Tubules, Proximal/metabolism ; Biological Transport/physiology ; Kidney/metabolism ; Tight Junctions/metabolism ; Water/metabolism
    Chemical Substances Claudin-2 ; Water (059QF0KO0R)
    Language English
    Publishing date 2023-06-30
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 184237-7
    ISSN 1470-8752 ; 0300-5127
    ISSN (online) 1470-8752
    ISSN 0300-5127
    DOI 10.1042/BST20220639
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: 'Art at Safe Homes': A pioneer study among COVID-19 patients and their treatment team.

    Bhattacharya, Nandan / Choudhury, Sonali / Roychowdhury, Mahua / Sinha, Meghanil / Mistri, Paromita / Bhattacharya, Ritwika / Maity, Sreya / Ghosh, Moumita / Dey, Pritam / Banik, Anirban

    Work (Reading, Mass.)

    2022  Volume 72, Issue 3, Page(s) 807–817

    MeSH term(s) COVID-19/epidemiology ; Humans ; Nursing Homes ; SARS-CoV-2
    Language English
    Publishing date 2022-06-11
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1394194-x
    ISSN 1875-9270 ; 1051-9815
    ISSN (online) 1875-9270
    ISSN 1051-9815
    DOI 10.3233/WOR-211220
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinoma.

    Standing, David / Arnold, Levi / Dandawate, Prasad / Ottemann, Brendan / Snyder, Vusala / Ponnurangam, Sivapriya / Sayed, Afreen / Subramaniam, Dharmalingam / Srinivasan, Pugazhendhi / Choudhury, Sonali / New, Jacob / Kwatra, Deep / Ramamoorthy, Prabhu / Roy, Badal C / Shadoin, Melissa / Al-Rajabi, Raed / O'Neil, Maura / Gunewardena, Sumedha / Ashcraft, John /
    Umar, Shahid / Weir, Scott J / Tawfik, Ossama / Padhye, Subhash B / Biersack, Bernhard / Anant, Shrikant / Thomas, Sufi Mary

    Molecular carcinogenesis

    2022  Volume 62, Issue 2, Page(s) 145–159

    Abstract: Doublecortin like kinase 1 (DCLK1) plays a crucial role in several cancers including colon and pancreatic adenocarcinomas. However, its role in squamous cell carcinoma (SCC) remains unknown. To this end, we examined DCLK1 expression in head and neck SCC ( ...

    Abstract Doublecortin like kinase 1 (DCLK1) plays a crucial role in several cancers including colon and pancreatic adenocarcinomas. However, its role in squamous cell carcinoma (SCC) remains unknown. To this end, we examined DCLK1 expression in head and neck SCC (HNSCC) and anal SCC (ASCC). We found that DCLK1 is elevated in patient SCC tissue, which correlated with cancer progression and poorer overall survival. Furthermore, DCLK1 expression is significantly elevated in human papilloma virus negative HNSCC, which are typically aggressive with poor responses to therapy. To understand the role of DCLK1 in tumorigenesis, we used specific shRNA to suppress DCLK1 expression. This significantly reduced tumor growth, spheroid formation, and migration of HNSCC cancer cells. To further the translational relevance of our studies, we sought to identify a selective DCLK1 inhibitor. Current attempts to target DCLK1 using pharmacologic approaches have relied on nonspecific suppression of DCLK1 kinase activity. Here, we demonstrate that DiFiD (3,5-bis [2,4-difluorobenzylidene]-4-piperidone) binds to DCLK1 with high selectivity. Moreover, DiFiD mediated suppression of DCLK1 led to G2/M arrest and apoptosis and significantly suppressed tumor growth of HNSCC xenografts and ASCC patient derived xenografts, supporting that DCLK1 is critical for SCC growth.
    MeSH term(s) Humans ; Apoptosis ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/genetics ; Cell Line, Tumor ; Doublecortin-Like Kinases ; G2 Phase Cell Cycle Checkpoints ; Head and Neck Neoplasms ; Intracellular Signaling Peptides and Proteins/genetics ; Protein Serine-Threonine Kinases/metabolism ; Squamous Cell Carcinoma of Head and Neck/genetics ; Animals
    Chemical Substances 3,5-bis(2,4-difluorobenzylidene)-4-piperidone ; DCLK1 protein, human (EC 2.7.1.11) ; Doublecortin-Like Kinases (EC 2.7.1.11) ; Intracellular Signaling Peptides and Proteins ; Protein Serine-Threonine Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2022-10-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1004029-8
    ISSN 1098-2744 ; 0899-1987
    ISSN (online) 1098-2744
    ISSN 0899-1987
    DOI 10.1002/mc.23472
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Insight in schizophrenia and its association with executive functions.

    Choudhury, Sonali / Khess, C R J / Bhattacharyya, Ranjan / Sanyal, Debasish

    Indian journal of psychological medicine

    2011  Volume 31, Issue 2, Page(s) 71–76

    Abstract: Background: Lack of insight or awareness of illness is most frequently observed in patients with schizophrenia, and it influences treatment compliance. It has been hypothesized that the frontal dysfunction may explain poor insight in schizophrenia.: ... ...

    Abstract Background: Lack of insight or awareness of illness is most frequently observed in patients with schizophrenia, and it influences treatment compliance. It has been hypothesized that the frontal dysfunction may explain poor insight in schizophrenia.
    Aim: The purposes of the study were to assess the degree of insight in schizophrenia and to examine the association, if any, between the degree of insight and executive functions in patients with schizophrenia.
    Materials and methods: In this pre-post study, 30 patients of both sexes diagnosed to have schizophrenia were assessed with the Scale to Assess Unawareness of Mental Disorder and Wisconsin Card Sorting Test (WCST). They were assessed once at the time of admission and then at the time of their discharge.
    Results: The study revealed that 70% of the subjects possessed poor awareness of mental disorder. There was significant improvement of insight over time. The degree of insight was significantly associated with the performance on WCST 2(nd) assessment. WCST scores were able to explain 42% of the variance in insight.
    Conclusion: Majority of schizophrenic patients possess poor insight. This poor insight is significantly associated with poor executive function. Hence poor insight may have a cognitive etiology.
    Language English
    Publishing date 2011-09-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2622378-8
    ISSN 0975-1564 ; 0253-7176
    ISSN (online) 0975-1564
    ISSN 0253-7176
    DOI 10.4103/0253-7176.63576
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.

    Dandawate, Prasad / Ghosh, Chandrayee / Palaniyandi, Kanagaraj / Paul, Santanu / Rawal, Sonia / Pradhan, Rohan / Sayed, Afreen Asif Ali / Choudhury, Sonali / Standing, David / Subramaniam, Dharmalingam / Padhye, Subhash B / Gunewardena, Sumedha / Thomas, Sufi M / Neil, Maura O' / Tawfik, Ossama / Welch, Danny R / Jensen, Roy A / Maliski, Sally / Weir, Scott /
    Iwakuma, Tomoo / Anant, Shrikant / Dhar, Animesh

    Gastroenterology

    2019  Volume 157, Issue 6, Page(s) 1646–1659.e11

    Abstract: Background & aims: The histone lysine demethylase 3A (KDM3A) demethylates H3K9me1 and H3K9Me2 to increase gene transcription and is upregulated in tumors, including pancreatic tumors. We investigated its activities in pancreatic cancer cell lines and ... ...

    Abstract Background & aims: The histone lysine demethylase 3A (KDM3A) demethylates H3K9me1 and H3K9Me2 to increase gene transcription and is upregulated in tumors, including pancreatic tumors. We investigated its activities in pancreatic cancer cell lines and its regulation of the gene encoding doublecortin calmodulin-like kinase 1 (DCLK1), a marker of cancer stem cells.
    Methods: We knocked down KDM3A in MiaPaCa-2 and S2-007 pancreatic cancer cell lines and overexpressed KDM3A in HPNE cells (human noncancerous pancreatic ductal cell line); we evaluated cell migration, invasion, and spheroid formation under hypoxic and normoxic conditions. Nude mice were given orthotopic injections of S2-007 cells, with or without (control) knockdown of KDM3A, and HPNE cells, with or without (control) overexpression of KDM3A; tumor growth was assessed. We analyzed pancreatic tumor tissues from mice and pancreatic cancer cell lines by immunohistochemistry and immunoblotting. We performed RNA-sequencing analysis of MiaPaCa-2 and S2-007 cells with knockdown of KDM3A and evaluated localization of DCLK1 and KDM3A by immunofluorescence. We analyzed the cancer genome atlas for levels of KDM3A and DCLK1 messenger RNA in human pancreatic ductal adenocarcinoma (PDAC) tissues and association with patient survival time.
    Results: Levels of KDM3A were increased in human pancreatic tumor tissues and cell lines, compared with adjacent nontumor pancreatic tissues, such as islet and acinar cells. Knockdown of KDM3A in S2-007 cells significantly reduced colony formation, invasion, migration, and spheroid formation, compared with control cells, and slowed growth of orthotopic tumors in mice. We identified KDM3A-binding sites in the DCLK1 promoter; S2-007 cells with knockdown of KDM3A had reduced levels of DCLK1. HPNE cells that overexpressed KDM3A formed foci and spheres in culture and formed tumors and metastases in mice, whereas control HPNE cells did not. Hypoxia induced sphere formation and increased levels of KDM3A in S2-007 cells and in HPNE cells that overexpressed DCLK1, but not control HPNE cells. Levels of KDM3A and DCLK1 messenger RNA were higher in human PDAC than nontumor pancreatic tissues and correlated with shorter survival times of patients.
    Conclusions: We found human PDAC samples and pancreatic cancer cell lines to overexpress KDM3A. KDM3A increases expression of DCLK1, and levels of both proteins are increased in human PDAC samples. Knockdown of KDM3A in pancreatic cancer cell lines reduced their invasive and sphere-forming activities in culture and formation of orthotopic tumors in mice. Hypoxia increased expression of KDM3A in pancreatic cancer cells. Strategies to disrupt this pathway might be developed for treatment of pancreatic cancer.
    MeSH term(s) Animals ; Carcinogenesis/genetics ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/mortality ; Carcinoma, Pancreatic Ductal/pathology ; Cell Line, Tumor ; DNA Methylation ; Datasets as Topic ; Doublecortin-Like Kinases ; Female ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Intracellular Signaling Peptides and Proteins/metabolism ; Jumonji Domain-Containing Histone Demethylases/genetics ; Jumonji Domain-Containing Histone Demethylases/metabolism ; Male ; Mice ; Middle Aged ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Promoter Regions, Genetic/genetics ; Protein Serine-Threonine Kinases/genetics ; Protein Serine-Threonine Kinases/metabolism ; Survival Analysis ; Up-Regulation ; Xenograft Model Antitumor Assays
    Chemical Substances Intracellular Signaling Peptides and Proteins ; Jumonji Domain-Containing Histone Demethylases (EC 1.14.11.-) ; KDM3A protein, human (EC 1.14.11.-) ; DCLK1 protein, human (EC 2.7.1.11) ; Doublecortin-Like Kinases (EC 2.7.1.11) ; Protein Serine-Threonine Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2019-08-20
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2019.08.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.

    Dandawate, Prasad / Kaushik, Gaurav / Ghosh, Chandrayee / Standing, David / Ali Sayed, Afreen Asif / Choudhury, Sonali / Subramaniam, Dharmalingam / Manzardo, Ann / Banerjee, Tuhina / Santra, Santimukul / Ramamoorthy, Prabhu / Butler, Merlin / Padhye, Subhash B / Baranda, Joaquina / Kasi, Anup / Sun, Weijing / Tawfik, Ossama / Coppola, Domenico / Malafa, Mokenge /
    Umar, Shahid / Soares, Michael J / Saha, Subhrajit / Weir, Scott J / Dhar, Animesh / Jensen, Roy A / Thomas, Sufi Mary / Anant, Shrikant

    Gastroenterology

    2019  Volume 158, Issue 5, Page(s) 1433–1449.e27

    Abstract: Background & aims: Prolactin (PRL) signaling is up-regulated in hormone-responsive cancers. The PRL receptor (PRLR) is a class I cytokine receptor that signals via the Janus kinase (JAK)-signal transducer and activator of transcription and mitogen- ... ...

    Abstract Background & aims: Prolactin (PRL) signaling is up-regulated in hormone-responsive cancers. The PRL receptor (PRLR) is a class I cytokine receptor that signals via the Janus kinase (JAK)-signal transducer and activator of transcription and mitogen-activated protein kinase pathways to regulate cell proliferation, migration, stem cell features, and apoptosis. Patients with pancreatic ductal adenocarcinoma (PDAC) have high plasma levels of PRL. We investigated whether PRLR signaling contributes to the growth of pancreatic tumors in mice.
    Methods: We used immunohistochemical analyses to compare levels of PRL and PRLR in multitumor tissue microarrays. We used structure-based virtual screening and fragment-based drug discovery to identify compounds likely to bind PRLR and interfere with its signaling. Human pancreatic cell lines (AsPC-1, BxPC-3, Panc-1, and MiaPaCa-2), with or without knockdown of PRLR (clustered regularly interspaced short palindromic repeats or small hairpin RNA), were incubated with PRL or penfluridol and analyzed in proliferation and spheroid formation. C57BL/6 mice were given injections of UNKC-6141 cells, with or without knockdown of PRLR, into pancreas, and tumor development was monitored for 4 weeks, with some mice receiving penfluridol treatment for 21 days. Human pancreatic tumor tissues were implanted into interscapular fat pads of NSG mice, and mice were given injections of penfluridol daily for 28 days. Nude mice were given injections of Panc-1 cells, xenograft tumors were grown for 2 weeks, and mice were then given intraperitoneal penfluridol for 35 days. Tumors were collected from mice and analyzed by histology, immunohistochemistry, and immunoblots.
    Results: Levels of PRLR were increased in PDAC compared with nontumor pancreatic tissues. Incubation of pancreatic cell lines with PRL activated signaling via JAK2-signal transducer and activator of transcription 3 and extracellular signal-regulated kinase, as well as formation of pancospheres and cell migration; these activities were not observed in cells with PRLR knockdown. Pancreatic cancer cells with PRLR knockdown formed significantly smaller tumors in mice. We identified several diphenylbutylpiperidine-class antipsychotic drugs as agents that decreased PRL-induced JAK2 signaling; incubation of pancreatic cancer cells with these compounds reduced their proliferation and formation of panco spheres. Injections of 1 of these compounds, penfluridol, slowed the growth of xenograft tumors in the different mouse models, reducing proliferation and inducing autophagy of the tumor cells.
    Conclusions: Levels of PRLR are increased in PDAC, and exposure to PRL increases proliferation and migration of pancreatic cancer cells. Antipsychotic drugs, such as penfluridol, block PRL signaling in pancreatic cancer cells to reduce their proliferation, induce autophagy, and slow the growth of xenograft tumors in mice. These drugs might be tested in patients with PDAC.
    MeSH term(s) Animals ; Antipsychotic Agents/pharmacology ; Antipsychotic Agents/therapeutic use ; Autophagy/drug effects ; Carcinoma, Pancreatic Ductal/blood ; Carcinoma, Pancreatic Ductal/drug therapy ; Carcinoma, Pancreatic Ductal/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Discovery ; Gene Knockdown Techniques ; Humans ; Injections, Intraperitoneal ; Janus Kinase 2/metabolism ; Male ; Mice ; Pancreas/pathology ; Pancreatic Neoplasms/blood ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/pathology ; Penfluridol/pharmacology ; Penfluridol/therapeutic use ; Prolactin/blood ; Prolactin/metabolism ; Receptors, Prolactin/antagonists & inhibitors ; Receptors, Prolactin/genetics ; Receptors, Prolactin/metabolism ; STAT3 Transcription Factor/metabolism ; Signal Transduction/drug effects ; Spheroids, Cellular ; Tissue Array Analysis ; Xenograft Model Antitumor Assays
    Chemical Substances Antipsychotic Agents ; Receptors, Prolactin ; STAT3 Transcription Factor ; STAT3 protein, human ; Penfluridol (25TLU22Q8H) ; Prolactin (9002-62-4) ; JAK2 protein, human (EC 2.7.10.2) ; Janus Kinase 2 (EC 2.7.10.2)
    Language English
    Publishing date 2019-11-29
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2019.11.279
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top